New Drug: Belzutifan for cancers associated with von Hippel-Lindau disease
|New Drug: Belzutifan for cancers associated with von Hippel-Lindau disease|
J Clin Oncol 2021;39: suppl 4555.
Srinivasan R, et al. Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC)
Altai Chemo Planner
Quickly Prepare Accurate Chemotherapy Orders
Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.